A monoclonal antibody is secreted by a single B lymphocyte clone which can only produce a kind of proprietary antibody against an antigen-determining cluster, and has the characteristics of single biological activity and particular specificity of binding with antigen.
The active sites of monoclonal antibody drugs involve a variety of tumor-related signaling pathways and targets. For example, the most common targets are epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), and epidermal growth factor receptor -2 (her-2 /neu, or egfr-2). Besides, there is a group of targets that are getting a lot of attention called “immune checkpoints”.
After the activation of immune cells that regulate the anti-tumor immune response, a variety of highly expressed receptors on the surface of immune cells bind to the highly expressed ligands on the surface of tumor cells to reduce the strength of the immune response, thus down-regulating the intensity of tumor-related immune response. These immunoregulatory sites are known as immune checkpoints. Currently, the most widely studied immune checkpoints are PD-1, PD-L1, and CTLA-4.
Targetmol provides 30 monoclonal antibody drugs, including the above immune checkpoint inhibitors and other types of targeted antibody inhibitors, for scientific research only.
Cat. No. | Product name | CAS No. | Purity | Chemical Structure |
---|---|---|---|---|
T25593 | Labetuzumab govitecan | 1469876-18-3 | 98% |
![]() |
Labetuzumab govitecan is an anti-CEACAM5/SN-38 antibody-drug conjugate for therapy of refractory or relapsing metastatic colorectal cancer. | ||||
T36656 | Anti-Spike-RBD Single Domain mAb | 98% |
|
|
Anti-Spike-RBD Single Domain mAb is a CHO cell derived Alpaca monoclonal VHH-huFc antibody, specifically binds to SARS-CoV-2 RBD with high affinity[1]. [1]. Chun... | ||||
T9927 | Panitumumab | 339177-26-3 | 98% |
|
Panitumumab is a fully human IgG2 monoclonal antibody targeting the epidermal growth factor receptor EGFR). | ||||
T10497 | Benralizumab | 1044511-01-4 | 98% |
![]() |
Benralizumab (MEDI-563) is an IL-5Rα-directed cytolytic monoclonal antibody that induces rapid, direct and nearly complete depletion of eosinophils via enhanced ... | ||||
T35389 | Sarilumab (anti-IL-6Rα) | 98% |
|
|
T9925 | Ofatumumab | 679818-59-8 | 98% |
|
Ofatumumab is a fully human monoclonal antibody to CD20 which appears to inhibit early-stage B lymphocyte activation | ||||
T36647 | Trastuzumab emtansine | 1018448-65-1 | 98% |
![]() |
Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab wit... | ||||
T9914 | Vedolizumab | 943609-66-3 | 98% |
![]() |
Vedolizumab is a humanized monoclonal antibody that targets the α4β7 integrin for the treatment of Crohn's disease and ulcerative colitis. | ||||
T35397 | Sacituzumab (anti-Trop-2) | 98% |
|
|
T35390 | Magrolimab (anti-CD47) | 98% |
|
|
T39595 | Disitamab vedotin | 2136633-23-1 | 98% |
![]() |
Disitamab vedotin (RC48) is an antibody-drug conjugate (ADC) comprising a monoclonal antibody against human epidermal growth factor receptor 2 (HER2) conjugated ... | ||||
T35386 | Elotuzumab (anti-SLAMF7) | 98% |
|
|
T36654 | Anti-SARS-CoV-2 Spike mAb (CR3022) | 98% |
|
|
Anti-SARS-CoV-2 Spike mAb (CR3022) is a a CHO cell derived human monoclonal IgG1 antibody. It binds to both S1 domain of SARS-CoV/SARS-CoV-2 Spike protein[1][2... | ||||
T36651 | Anti-MERS-2E6 mAb | 98% |
|
|
Anti-MERS-2E6 mAb (MERS-2E6; MERS Antibody-2E6), a human neutralizing antibody IgG1 (CHO expressed) that can compete for the binding of the virus Spike protein t... | ||||
T9922 | Matuzumab | 339186-68-4 | 98% |
|
Matuzumab is a humanized monoclonal antibody used in cancer treatment. It has a high affinity for EGFR frequently associated with the growth of blood vessels in ... | ||||
T39730 | Datopotamab deruxtecan | 2238831-60-0 | 98% |
![]() |
Datopotamab deruxtecan (DS-1062; Dato-DXd) is a trophoblast cell surface antigen 2 (TROP2)-directed antibody-drug conjugate (ADC) . Datopotamab deruxtecan has a ... | ||||
T35385 | Isatuximab (anti-CD38) | 98% |
|
|
T9923 | Nimotuzumab | 828933-51-3 | 98% |
|
Nimotuzumab is a humanized therapeutic monoclonal antibody against epidermal growth factor receptor EGFR). | ||||
T38951 | Isatuximab | 1461640-62-9 | 98% |
![]() |
Isatuximab is a monoclonal antibody targeting the transmembrane receptor and ectoenzyme CD38 , a protein highly expressed on hematological malignant cells, inclu... | ||||
T35394 | Sintilimab (anti-PD-1) | 98% |
|
|